The headline reads as positive (74% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The rest of the picture is mixed, so the headline alone is not enough for a clear call.
Stocks › PFE
Pfizer, Inc. (PFE) stock analysis
SKIP 11% confidence · analysed Oct 14, 2026
On Oct 14, 2026, our model rated Pfizer, Inc. (PFE) SKIP with 11% confidence at a price of $28.37. That means the signals cancel out; the model sees no clear edge either way.
SectorHealthcare
IndustryDrug Manufacturers - General
Market cap161.70B
Analysed price$28.37
Technical picture
The 14-day RSI is 53, close to the neutral 50 line, so momentum is balanced.
MACD is below its signal line, so short-term momentum is pointing down.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is about normal (0.8x the 20-day average).
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $27.80 and the swing low is $23.21; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 13.01, which looks expensive relative to its growth.
The company reports a profit margin of 6.8% and revenue growth of +2.6%.
In its latest quarter it earned $0.77 per share, which beat the $0.68 analysts expected, with revenue +2.6% year over year.
Wall Street's average rating is 2.5 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $29.26.
The next earnings report is expected around Nov 3, 2026; prices often move sharply around earnings.
The model's one-paragraph read
No clear edge (SKIP) — composite score +0.11 (SKIP). Technicals: RSI 52.94, MACD bearish, price above SMA50. Fundamentals: PEG 13.01, margin 6.8%, revenue growth 2.6%. Financial results: YoY revenue +2.6%, last EPS surprise +13.2%, next earnings 2026-11-03. Smart Money Concepts: BOS bullish (trend continuation). FinGPT news read: positive. Memory: 1 prior look(s). Reference price $29.19; no trade levels (SKIP).
Past ratings for PFE
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 14, 2026 | SKIP | 11% | $28.37 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on PFE
Oct 14, 2026 · Pfizer partners with Enodia Therapeutics in $500m drug deal
- Oct 14, 2026: Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026 (Business Wire)
- Oct 14, 2026: Pfizer partners with Enodia Therapeutics in $500m drug deal (Pharmaceutical Technology)
- Oct 13, 2026: Pfizer or Enbridge: Only One Gets My Dividend Dollars for the Next 10 Years (TIKR)
- Oct 13, 2026: What Does Bristol-Myers Squibb Offer That Pfizer Does Not? (Trefis)
Other Healthcare stocks we cover
PGNY · PHR · PRGO · SDZNY · SLS · SNN · STE · TCMD · TKNO · UNH · UTHR · ZBH
Frequently asked questions
Is PFE a buy right now?
As of Oct 14, 2026, our automated model rates Pfizer, Inc. (PFE) SKIP with 11% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Pfizer, Inc. report earnings next?
The next earnings report is expected around Nov 3, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.